The use of surrogate endpoints in solid and haematological cancers

Ash Paul, Medical Director EoE Specialised Commissioning Group, UK, shared a post on X:

“Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more.”

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more

Authors: Timothée Olivier, Alyson Haslam, Dagney Ochoa, Eduardo Fernandez and Vinay Prasad.

Source: Ash Paul/X